The analysis showed that the drug “was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance”, a finding not reported in published trials [20] .
← all excerpts
Impact of inclusion of industry trial results registries as an information source for systematic reviews.
1
—
—